menu search

Fda approves eisai and biogen's new alzheimer's therapy

The Food and Drug Administration on Friday approved Eisai and Biogen's alzheimer's treatment lecanemab,...

January 6, 2023, 2:37 pm

The fda just approved a new alzheimer's drug that's set to be a blockbuster

The new drug, called Leqembi, slowed the rate of cognitive decline in alzheimer's patients by 27%....

January 6, 2023, 2:21 pm

Fda approves alzheimer's drug that slowed cognitive decline in clinical trial

The FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from ...

January 6, 2023, 2:11 pm

Jefferies' michael yee on biogen as fda could be on the verge of approving alzheimer's drug

Michael Yee, Jefferies managing director, joins 'The Exchange' to discuss biotech and the FDA's looming decision on Biogen's second ...

January 6, 2023, 2:09 pm

Lecanemab alert: what would alzheimer's drug approval mean for biogen (biib) stock?

One stock that's trading in the right direction today is prominent mega-cap biotech stock Biogen (NASDAQ: BIIB ). Shares of BIIB stock have surged a...

January 6, 2023, 2:07 pm

Biogen could get a second alzheimer's ok — but will wild card medicare bite?

Biogen stock jumped Friday ahead of an FDA decision on the accelerated approval of its experimental alzheimer<...

January 6, 2023, 10:41 am

alzheimer's drug decision day: fda to decide on biogen and eisai treatments

CNBC's Meg Tirrell joins 'Squawk Box' to discuss the big day ahead for alzheimer's medicine....

January 6, 2023, 8:46 am

Amid criticism for its handling of another alzheimer's drug, fda will decide this week whether to approve lecanemab

The Food and Drug Administration is expected to make a decision on whether to approve a new alzheimer's...

January 3, 2023, 2:47 pm

Eisai and biogen's lecanemab: a flawed treatment for alzheimer's disease

Lecanemab only significantly slows down the progression of alzheimer's disease in APOE4 carriers. Lecan...

December 30, 2022, 5:22 pm

House democrats fault fda for collaborating improperly with biogen

A new report from House Democrats found that the U.S. Food and Drug Administration inappropriately collaborated with Biogen before approving its ...

December 30, 2022, 9:26 am

House committee questions biogen drug approval process

The FDA's approval process of Biogen's alzheimer's drug was questioned in a Congressional report releas...

December 30, 2022, 12:20 am

Biogen's alzheimer's drug likely to be approved with warning labels

A new as-yet-unreported death among those taking Biogen's Lecanemab in an extended post-Phase 3 study has emerged. Biogen's Lecanemab has a PDUFA date...

December 29, 2022, 1:41 pm

Congressional report: u.s. fda broke own protocols in approving biogen alzheimer's drug

The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen's ...

December 29, 2022, 1:05 pm

Neurological biomarkers market size is expected to surpass us$ 12.5 bn in the next decade. between 2023 and 2033, to register a 4.6% cagr – future market insights, inc.

Rise in Cases of alzheimer’s disease amongst the Geriatric Population is likely to Augment the Demand...

December 27, 2022, 9:00 am

Biovie: 9 reasons for enthusiasm

Over the past few months, BioVie has reported good data from a Phase 2 trial in alzheimer's and a Phase...

December 21, 2022, 11:26 pm

Why is synaptogenix (snpx) stock plummeting 70% today?

Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the ...

December 16, 2022, 3:30 pm

Is anavex life sciences a buy?

It still needs to prove that its lead program is as effective as it claims for treating alzheimer's....

December 13, 2022, 9:45 am

Synaptogenix: bryostatin for alzheimer's, as binary as can be

Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in alzheimer's di...

December 9, 2022, 11:50 am

Axsome: more catalysts stacking for 2023

In its early launch for depression, Axsome Therapeutics, Inc.'s Auvelity is already garnering robust market adoption. Demonstrating its therapeutic pr...

December 8, 2022, 12:05 pm

Why 2023 could be a big year for biogen

Investors will soon learn if the company's alzheimer's treatment gets the green light....

December 7, 2022, 10:38 am


Search within

Pages Search Results: